Fertin Pharma A/s

Philip Morris Products S.a.

Nordiccan A/s

Ncp Nextgen A/s

Jesper Neergaard

Bruno Provstgaard Nielsen

Heidi Ziegler Bruun

My Ly Lao Stahl

Bine Hare Jakobsen

Jesper Thorsen

Bjarne Vestbö

Birgitte Kringelum Breindal

Anayo Ogbonna

An oral pouched product is disclosed, the oral pouched product includes a saliva permeable pouch, a non-tobacco pouch composition, the pouch composition includes heat-treated fibers, nicotine in an amount of 0.1-5.0% by weight of the pouch compositions, water in an amount 15-65% by weight of the pouch composition, at least one sugar alcohol, and less than 0.5% preservative by weight of the pouch composition. Also, a method for manufacturing an oral pouched product is disclosed.

Oral pouched product

An oral pouched product is disclosed, the pouched product comprising a saliva permeable pouch and a pouch composition, the pouch composition comprising a powdered composition, water, and a liquid flavor composition, wherein the liquid flavor composition is added to the powdered composition after the water. A further oral pouched product and a method of manufacturing an oral pouched product is disclosed.

Pouched product with liquid flavor composition

A nicotine pouch composition is disclosed, the pouch composition includes at least one sugar alcohol, at least one water-insoluble fiber, water in an amount of 8-65% by weight of the composition, and nicotine. Also, an oral pouched nicotine product and a method for manufacturing an oral pouched product is disclosed.

Nicotine pouch composition

The invention relates to a solid pharmaceutical tablet for oral delivery, the tablet comprising calcium carbonate in an amount of more than 30% by weight of the tablet and organic water-insoluble components in an amount of more than 20% by weight of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing the organic water-insoluble components, and wherein the tablet is adapted to release more than 80% of the calcium carbonate within 5 minutes of mastication.

Solid pharmaceutical tablet

An oral pouched product is disclosed, the oral pouched product includes a saliva permeable pouch, a pouch composition, the pouch composition includes heat-treated fibers, nicotine, water in an amount of less than 65% by weight of the pouch composition, and at least one sugar alcohol. Also, a method for manufacturing an oral pouched product is disclosed.

The present invention relates to a nicotine delivery product comprising, or even consisting essentially of, a population of nicotine-loaded cation exchange resin particles, said population comprises at least 50% (w/w) particles having a size in the range of 90-300 micron which provides an improved nicotine stability to oral dosage forms comprising the nicotine delivery product. The invention furthermore relates to methods of producing the nicotine delivery product and the oral dosage forms and to the use of the nicotine delivery product.

Nicotine delivery product, related uses and oral dosage forms, and methods of production

A medical chewing gum including gum base polymers and one or more cannabinoids as an active pharmaceutical ingredient, the gum base polymers including polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight of the gum base polymers, wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer.

Medical chewing gum comprising cannabinoid

A nicotine chewing gum is disclosed, the nicotine chewing gum having gum base polymers, nicotine, and microcrystalline cellulose as a carrier for the nicotine, the gum base polymers include polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight of the gum base polymers, and the gum base polymers include 20-95% by weight of polyvinyl acetate and 5-80% by weight of vinyl laurate-vinyl acetate copolymer. Also, a method for producing a nicotine chewing gum is disclosed.

Chewing gum comprising nicotine

The invention relates to a medical chewing gum comprising gum base polymers and an active pharmaceutical ingredient, the gum base polymers comprising polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight, wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and -80% by weight of vinyl laurate-vinyl acetate copolymer, and wherein the chewing gum contains no polyterpene resins and no resins based on gum rosin, wood rosin or tall oil resin.

Medical chewing gum

The present invention relates to a chewing gum having a high Surface Area to Volume ratio (SAV ratio), wherein said chewing gum comprises a water insoluble gum base matrix, a water soluble bulk portion and nicotine, wherein the gum base matrix, nicotine and the bulk portion are mixed and extruded to form a final extruded chewing gum product having a SAV ratio above 0.7, and wherein sustained release of nicotine is facilitated by adding 0.1-10% of C8-C10 triglycerides by weight of the chewing gum.

Growing community of inventors

Aabenraa, Denmark

Jesper Neergaard